New in town: Hae! Mee — 25-year-old Bai Nian 2nd-gen sells prawn noodles with palm-sized prawns
Hae! Mee, a new prawn noodle stall situated at Chai Chee ESR BizPark food court recently opened to the public on 15 May 2025. For all those who find the name similar to Hae! Claypot at Eunos, you're right! Both stalls are actually opened by the 2nd-gen of siblings whose parents run the popular Bai Nian Yong Tau Foo franchise.
25-year-old owner Chantal Pang, a single mother of 2, didn't exactly have a good relationship with her family. She got pregnant at 19. Despite her parents' advice and disapproval, she still ran away from home with her ex-husband. As a result, her family decided to cut ties.
Life outside was tough for Chantal as she juggled multiple jobs while taking care of her newborn. As she grew older, she realised that her parents just wanted the best for her and didn't want her to live a life of regret.
Thus, Chantal sincerely wanted to reconcile with her family and regain their trust. Her brother asked if she wanted to work at the claypot shop. Since she had amassed some experience during her younger days when helping out at her parent's stall, she agreed.
Over time, she reconciled with them and her kids got to connect with their grandparents. She later decided to build her own F&B brand that symbolises home and growth, and that's when Hae! Mee came to fruition.
To ensure Chantal receives only the freshest palm-sized prawns daily, her brother Tommy, who had working relationships with seafood suppliers at Jurong Fishery Port seafood, connected her with them.
There are 4 options of noodles available — kway teow, yellow mee, and bee hoon — each served either dry or soup. The Signature Big Prawn Noodle (S$11.90), the chef's choice, contains 2 massive prawns, prawn paste, pork slices and pork lard.
If you don't particularly fancy large prawns, you can go for the normal sized ones like the Prawn Noodle (S$6.90) and Classic Prawn Noodle (S$8.90), which come with 4 prawns each. The only difference between the two is that the latter has 2 additional fried beancurd rolls.
You can also take your bowl of noodles to the next level by adding ingredients like Liver (S$1), Pig Skin (S$1) and Prawn Paste (S$2).
The menu also has delightful side dishes such as Golden Prawn Pancake (S$5.90), Golden Prawn Roll (S$5.90), and Hae Signature Fried Prawn (S$6.90 for 6 pieces). These are perfect for passing around to share among your family and friends!
Seeking a new prawn noodle spot to makan? Then head to Hae! Mee and see if they meet your standards.
Hong Lim Prawn Noodle: Highly-raved spot serving up gao, umami-packed prawn noodles
The post New in town: Hae! Mee — 25-year-old Bai Nian 2nd-gen sells prawn noodles with palm-sized prawns appeared first on SETHLUI.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HAE Q1 Earnings Call: Revenue Misses Expectations, Margin Expansion and Product Focus Highlighted
Blood products company Haemonetics (NYSE:HAE). fell short of the market's revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $330.6 million. Its non-GAAP EPS of $1.24 per share was 1.6% above analysts' consensus estimates. Is now the time to buy HAE? Find out in our full research report (it's free). Revenue: $330.6 million (3.7% year-on-year decline) Adjusted EPS: $1.24 vs analyst estimates of $1.22 (1.6% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $4.85 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 21.6%, up from 8.7% in the same quarter last year Organic Revenue was flat year on year (10.2% in the same quarter last year) Market Capitalization: $3.35 billion Haemonetics reported first quarter results marked by revenue declines, but management emphasized the impact of its evolving product portfolio and operational changes. CEO Chris Simon attributed performance to strong growth in the Hospital segment, led by technologies such as TEG and VASCADE, and highlighted the successful divestiture of the Whole Blood business. He noted that expanded adoption of next-generation products, particularly in Plasma technology, contributed to margin improvement. Simon also referenced the company's ongoing focus on higher-margin product categories and operational discipline as factors that contributed to the quarter's profitability, stating, 'Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets.' Looking forward, Haemonetics' guidance reflects a cautious outlook as the company anticipates ongoing headwinds from portfolio transitions and external market factors. Management expects organic growth to be driven mainly by increased utilization and share gains in Plasma and Hospital technologies, while acknowledging a potential rebound in collection volumes later in the year. CFO James D'Arecca warned that reported revenue is expected to decline due to the completed Whole Blood divestiture and continued impacts from the CSL contract transition, but emphasized that gross margin expansion and disciplined cost management should support profitability. D'Arecca stated, 'We expect adjusted operating margin to improve by 200 to 300 basis points... supported by continued gains in adjusted gross margin.' Management traced the quarter's performance to a mix of product portfolio shifts, margin expansion, and strategic focus on high-growth segments, while also pointing to contract transitions and market-specific headwinds. Hospital segment momentum: Growth was led by Hospital products, including Blood Management Technologies and Interventional Technologies, with double-digit increases in both franchises. The TEG viscoelastic testing platform saw accelerated adoption, particularly with the launch of the HN cartridge, driving new account openings and transitions from older models. Vascular Closure advances: The VASCADE MVP and MVP XL devices in the Interventional Technologies franchise delivered over 25% growth due to new account openings and increased U.S. and Japanese utilization. However, legacy VASCADE products for coronary and peripheral procedures saw slower growth, which management aims to address through focused sales efforts. Plasma technology adoption: Plasma revenue was buoyed by the adoption of next-generation technologies like Persona and Express Plus, resulting in share gains and increased margins. Management highlighted new multi-year agreements with major collectors, which are expected to continue contributing to growth. Portfolio transformation and divestitures: The completed divestiture of the Whole Blood business enabled resource reallocation to higher-growth, higher-margin areas. This shift contributed to the significant improvement in overall operating margins and supported disciplined capital allocation, including share repurchases. Leadership and organizational changes: The promotions of Roy Galvin to Chief Commercial Officer and Frank Chan to Chief Operating Officer were cited as key steps to strengthen commercial execution and operations, particularly in supporting the Hospital business's long-term growth plans. Haemonetics expects near-term revenue to be shaped by portfolio transitions, while focusing on margin gains and product adoption to drive future growth and profitability. Product utilization and share gains: Management anticipates that growth will be led by increased utilization of existing devices, especially in Plasma and Vascular Closure, supported by recent extended contracts with major plasma collectors. New hospital product launches and technology conversions are expected to offset headwinds in legacy product lines. Margin expansion and cost discipline: The company projects further improvement in operating margins through portfolio mix shifts towards higher-margin products and ongoing cost control measures. Approximately $30 million in savings are expected over the next two years through regional alignment and operational efficiencies. External risks and market headwinds: Haemonetics identified tariff exposure, timing of contract transitions, and softness in the Chinese market as areas of uncertainty. While management expects U.S. and European momentum to offset challenges, external factors could impact both revenue progression and profitability in the coming quarters. In the next few quarters, the StockStory team will monitor (1) the pace of technology adoption and utilization in the Plasma and Hospital segments, (2) execution against targeted improvements in Vascular Closure—especially legacy product turnaround efforts, and (3) margin performance as cost savings and portfolio transformation initiatives take hold. Progress on regulatory approvals and new product launches will also be important milestones. Haemonetics currently trades at a forward P/E ratio of 14.2×. Should you double down or take your chips? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Three years on, Zhongshan shows visible progress in "High-Quality Development Project"
ZHONGSHAN, China, June 5, 2025 /PRNewswire/ -- Since the launch of the "High-Quality Development Project for Counties, Towns and Villages," Zhongshan City has implemented the "1310" development strategy put forward by CPC Guangdong Provincial Committee. Guided by these principles and following the directives given by Huang Kunming, Secretary of the CPC Guangdong Provincial Committee, during his visit to Zhongshan, the city has made this initiative its top priority. After three years of determined effort, the project is now yielding visible and meaningful results. Zhongshan has advanced the project by focusing on transformation and upgrading of inefficient industrial parks in villages and towns and water pollution control. Over the past three years, the city has cleared and redeveloped more than 48,000 mu (around 3,200 hectares) of inefficient industrial land across its villages and towns. These efforts have laid the groundwork for ten major cross-town industrial clusters in sectors such as new energy, biomedicine, smart home technologies, and new materials. The renewed land has attracted nearly 190 billion yuan (US$26.37 billion) in new investment. Zhongshan's industrial investment has maintained double-digit growth for 29 consecutive months, doubling in size over the past three years. Village-level collective property values have generally increased more than tenfold, resulting in a dramatic transformation of the urban-rural landscape. Huang highly recognized the initiative as a true development and livelihood project. Zhongshan's commitment to water pollution control has also delivered impressive results. Its three-year battle to tackle water pollution earned strong recognition from the Ministry of Ecology and Environment (MEE), the South China Inspection Bureau of the MEE, the CPC Guangdong Provincial Committee and the provincial government. China Environment News ran a front-page feature on Zhongshan's achievements, hailing the city's efforts as a high-scoring answer sheet in water management and a model for building beautiful rivers and lakes. Through the twin drivers of industrial renewal and water governance, Zhongshan has unlocked broader momentum in high-quality development. For 20 consecutive months, investment in technological upgrades has grown at over 15%. The city now ranks first in the Pearl River Delta in the digital transformation rate of its enterprises above designated size and was selected as a national pilot city for the digitalization of small and medium-sized enterprises. Zhongshan is also promoting the integration of agriculture, culture, and tourism. Under its "1-1-1-3-8" tourism development strategy, the city is shaping a new city brand that combines authentic local charm with the vibrant, high-quality lifestyle of the Greater Bay Area. In 2024, tourist visits to Zhongshan rose by 24.3%, while tourism revenue jumped 28.2%. Zhongshan has launched a series of targeted campaigns to improve the rural living environment, focusing on issues such as makeshift field huts, enclosed barriers, transport hubs, and under-bridge spaces. The city has completed 23,000 clean-up and renovation tasks under its "three-line" initiative—referring to the relocation and repair of overhead power lines, telecommunication lines, and broadcast television lines—and dismantled or upgraded 38,000 temporary field structures. Following a "one village, one policy; one house, one plan" approach, Zhongshan has renovated nearly 59,000 rural homes, significantly enhancing the overall appearance, harmony, and livability of its villages. Guo Wenhai, Secretary of the CPC Zhongshan Municipal Committee, said that the city will remain focused on three major goals: building a strong economy, creating beautiful urban and rural areas, and improving social governance. These efforts align with the Guangdong Provincial Committee's priorities in industrial development, environmental enhancement, public services, institutional reform, and encouraging social participation. Looking ahead, Zhongshan aims to deliver even more visible, tangible, and impactful outcomes through the high-quality development project. Video - - View original content to download multimedia: SOURCE City of Zhongshan Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Fei Zai Prawn Noodles reopens after 2-month hiatus
We're starting June off with some great news — Pasir Panjang's beloved prawn mee stall, Fei Zai (Fat Boy) Pork Rib Prawn Noodles, reopened on 2 Jun after a 2-month hiatus. Earlier in Mar, Fei Zai announced through a Facebook post that they would be going on a 2-month extended break from 24 Mar to Jun, after 20 years of operation at the same outlet. However, they didn't disclose the reason why. A netizen claimed to have spoken with the owner before the break, who allegedly shared that the stall would be closed for good due to a rent increase. Regardless of the reason, many customers are just excited to get their prawn mee fix at Fei Zai again after 2 long months. One such customer even 'went down almost every weekend just to see when will he be back.' There weren't many updates on Fei Zai's socials in this time, so can you blame him? Now the question is, have the owners lost their touch after the break? You'd be pleased to know that, based on another patron who headed down on their first day of reopening, 'the standard is still great'! While the standard remained the same, the prices have unfortunately increased, each item by S$0.50. Here are some of the prices you should take note of before heading down. The cheapest dish on Fei Zai's menu is their Prawn Noodle, priced at S$4.50 and S$5.50. The most popular item on their menu, as depicted by the stall's name, is the Prawn Noodle with Pork Rib (S$6/S$7). If you're already making the trip down to Fei Zai, might as well go all out and get their Big Prawn with Pork Rib (S$10/S$12), right? Don't worry about making your money's worth, as the small bowl already comes with 2 luxuriously large prawns and pork ribs, immersed in a umami-packed broth scattered with shallots. Feel free to customise every component of your dish to your preference, from the soup/dry versions to your choice of noodle between yellow mee, kway teow or bee hoon. This is your sign to try a bowl of this prawn mee, as Fei Zai (Fat Boy) Pork Rib Prawn Noodles reopens. They supposedly close at 1pm, but most dishes are sold out by 11am, so I'd recommend heading down first thing in the AM! We tried Singapore's best-rated prawn noodles The post Fei Zai Prawn Noodles reopens after 2-month hiatus appeared first on
